spirapril and Cough

spirapril has been researched along with Cough* in 3 studies

Trials

1 trial(s) available for spirapril and Cough

ArticleYear
Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma.
    Chest, 1992, Volume: 101, Issue:4

    Twenty-one subjects with known bronchial hyperreactivity were prospectively randomized in double-blind fashion to receive one of two angiotensin-converting enzyme inhibitors (ACE-I), enalapril or spirapril, for three weeks. Spirometry and methacholine provocation were performed prior to, during, and following ACE-I usage. Three of 21 subjects developed a nonproductive cough. However, only one subject wheezed slightly. Spirometry and bronchial reactivity (PD20) were unchanged throughout the study.

    Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cough; Double-Blind Method; Drug Tolerance; Enalapril; Female; Humans; Male; Methacholine Chloride; Middle Aged; Prospective Studies; Single-Blind Method

1992

Other Studies

2 other study(ies) available for spirapril and Cough

ArticleYear
Clinical experience with spirapril in human hypertension.
    Journal of cardiovascular pharmacology, 1999, Volume: 34 Suppl 1

    The efficacy and tolerability of spirapril were evaluated in a prospective, multicentre, post-marketing surveillance study on the treatment of arterial hypertension in 5000 patients, most of whom had received a single daily dose of 6 mg spirapril. The study was carried out by internists and general practitioners. In accordance with placebo-controlled clinical trials, spirapril was proven to be a very effective antihypertensive drug, in respect of both the mean reduction in systolic and diastolic blood pressure achieved as well as the responder rate of 89.4% and 85.4% for systolic and diastolic blood pressure, respectively. Efficacy was equally good in single drug treatment and combination treatment. Differentiated evaluation of blood pressure values in respect of the severity of hypertension on the basis of the World Health Organization classification showed a clear relationship between the baseline blood pressure and the reduction in blood pressure. The higher the baseline blood pressure, the more pronounced was the antihypertensive efficacy; a particular reduction in diastolic blood pressure being observed. Tolerability was also good, with an incidence of side effects of only 2.9%. Coughing was observed in only 0.88% of patients. Thus spirapril is seen to be an effective and well-tolerated antihypertensive drug whose efficacy is clearly related to baseline blood pressure and thus is also very effective in the treatment of severe forms of hypertension.

    Topics: Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Cough; Enalapril; Hemodynamics; Humans; Hypertension; Polypharmacy; Product Surveillance, Postmarketing

1999
Cough induced activity of spirapril in rats.
    General pharmacology, 1993, Volume: 24, Issue:6

    1. We examined the effect of spirapril, a potent angiotensin converting enzyme (ACE) inhibitor, on the number of capsaicin-induced coughs in rats and compared with that of enalapril. 2. Chronic treatment with enalapril, at doses of 1 and 3 mg/kg, p.o., significantly and dose-dependently enhanced the number of capsaicin-induced coughs. 3. Chronic treatment with higher dose of spirapril (3 mg/kg, p.o.) also significantly enhanced the number of capsaicin-induced coughs. However, lower dose (1 mg/kg, p.o.) of spirapril had no significant effect on the number of capsaicin-induced coughs. 4. These results suggest that cough induced activity, one of the most serious side effects associated with chronic treatment with ACE inhibitors, of spirapril is relatively lower than that of enalapril.

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cough; Enalapril; Injections, Intravenous; Male; Rats; Rats, Sprague-Dawley; Reflex

1993